ISSN: 1309 - 3843 E-ISSN: 1307 - 7384
FİZİKSEL TIP VE REHABİLİTASYON
BİLİMLERİ DERGİSİ
www.jpmrs.com
Kayıtlı İndexler


ORIJINAL ARAŞTIRMA

Fibromiyalji Sendromlu Hastalarda Kinezyofobiyi Etkileyen Faktörler ve Kinezyofobinin Tedaviye Uyum Sürecine Etkisi
Factors Affecting Kinesiophobia in Patients with Fibromyalgia Syndrome and the Effect of Kinesiophobia on Treatment Compliance Process
Received Date : 14 Oct 2021
Accepted Date : 30 Nov 2021
Available Online : 09 Dec 2021
Doi: 10.31609/jpmrs.2021-86615 - Makale Dili: TR
J PMR Sci. 2022;25(2):213-19
ÖZET
Amaç: Bu çalışmanın amacı, fibromiyalji sendromu (FMS) tanılı hastalarda, kinezyofobiyi etkileyen faktörleri belirlemek ve kinezyofobinin tedavi programına uyum sürecine etkisini değerlendirmektir. Gereç ve Yöntemler: Prospektif ve kesitsel olarak planlanan çalışmaya 1 Temmuz-15 Eylül 2021 tarihleri arasında Gaziler Fizik Tedavi ve Rehabilitasyon Eğitim ve Araştırma Hastanesine başvuran 22 FMS tanılı kadın hasta ile 22 sağlıklı kadın gönüllü dâhil edildi. Fibromiyalji Etki Anketi (FEA), Tampa Kinezyofobi Ölçeği (TKÖ), Yaşam Memnuniyeti Skalası (YMS), vizüel analog skala (VAS) değerlendirmeler için kullanıldı. FMS tanılı hastalar, TKÖ skoruna göre “düşük seviye kinezyofobi (n=12)” ve “yüksek seviye kinezyofobi (n=10)” olarak 2 gruba ayrıldı. Ayrıca düzenli tempolu yürüyüş yapmaları, düzenli ilaç kullanımları, geleneksel ve tamamlayıcı tıp yöntemlerine başvurma sıklıkları, ağrılarından dolayı sağlık kuruluşuna başvurma sıklıkları 5’li Likert skalasına göre değerlendirildi. Bulgular: FMS tanılı hasta grubunda FEA, TKÖ ve VAS değerleri istatistiksel olarak anlamlı derecede yüksekti, ancak YMS değerleri bakımından anlamlı farklılık saptanmadı. FMS tanılı hasta grubunun düzenli ilaç kullanımları ve ağrılarından dolayı sağlık kuruluşuna başvurma sıklıkları istatistiksel olarak anlamlı derecede yüksekti. Düşük seviye kinezyofobi ve yüksek seviye kinezyofobi grupları arasında hastalık süresi bakımından anlamlı farklılık saptanmazken, yüksek seviye kinezyofobi grubunda VAS ve FEA skorları anlamlı olarak daha yüksekti ve sağlık kuruluşuna başvurma sıklıkları daha fazla idi. Sonuç: Her hastanın biyopsikososyal yönleri olduğu göz önünde bulundurularak, kinezyofobiyi değerlendiren ölçekler tedavi programını oluştururken faydalı bilgiler sağlayabilir. Klinisyenler, FMS tanılı hastaları değerlendirirken kinezyofobi varlığını dikkate almalı ve kinezyofobinin önemi ve tedavi stratejileri hakkında hastaları bilgilendirmelidir.
ABSTRACT
Objective: To determine the factors affecting kinesiophobia in patients with fibromyalgia syndrome (FMS) and to evaluate the effect of kinesiophobia on the adaptation process to the treatment program. Material and Methods: Twenty-two female patients with FMS and 22 healthy female volunteers who applied to the Gaziler Physical Therapy and Rehabilitation Training and Research Hospital between July 1 and September 15, 2021 were included in the prospective and cross-sectional study. The Fibromyalgia Impact Questionnaire (FIQ), The Tampa Scale for Kinesiophobia (TSK), the Satisfaction with Life Scale (SWLS), and visual analogue scale (VAS) were used for evaluations. Patients diagnosed with FMS were divided into two groups as “low level kinesiophobia (n=12)” and “high level kinesiophobia (n=10)” according to TSK score. In addition, regular brisk walking, regular drug use, the frequency of applying to traditional and complementary medicine methods, the frequency of applying to a health institution due to pain were evaluated according to a 5-point Likert scale. Results: FIQ, TSK and VAS values were statistically significantly higher in the patient group diagnosed with FMS, but no significant difference was found in terms of SWLS values. Frequency of applying to health institutions due to pain and regular drug use in the patient group diagnosed with FMS was statistically significantly higher. While no significant difference was found between the low-level kinesiophobia and highlevel kinesiophobia groups in terms of disease duration, the VAS and FIQ scores were significantly higher in the high-level kinesiophobia group, and the frequency of applying to a health institution was higher. Conclusion: Considering that each patient has biopsychosocial aspects, scales assessing kinesiophobia can provide useful information while creating the treatment program. Clinicians should consider the presence of kinesiophobia when evaluating patients with FMS and should inform patients about the importance of kinesiophobia and treatment strategies.
REFERENCES
  1. Sarzi-Puttini P, Giorgi V, Marotto D, et al. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020;16:645-60. [Crossref]  [PubMed] 
  2. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995; 38:19-28. [Crossref]  [PubMed] 
  3. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl. 2005;75:6-21. Erratum in: J Rheumatol Suppl. 2005;32:2063. [PubMed] 
  4. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76:318-28. [Crossref]  [PubMed] 
  5. Nijs J, Roussel N, Van Oosterwijck J, et al. Fear of movement and avoidance behaviour toward physical activity in chronic-fatigue syndrome and fibromyalgia: state of the art and implications for clinical practice. Clin Rheumatol. 2013;32:1121-9. [Crossref]  [PubMed] 
  6. Gregg CD, McIntosh G, Hall H, et al. The relationship between the Tampa Scale of Kinesiophobia and low back pain rehabilitation outcomes. Spine J. 2015;15:2466-71. [Crossref]  [PubMed] 
  7. Wiech K, Tracey I. The influence of negative emotions on pain: behavioral effects and neural mechanisms. Neuroimage. 2009;47:987-94. [Crossref]  [PubMed] 
  8. Koçyiğit BF, Akaltun MS. Kinesiophobia levels in fibromyalgia syndrome and the relationship between pain, disease activity, depression. Arch Rheumatol. 2020;35:214-9. [Crossref]  [PubMed]  [PMC] 
  9. Turk DC, Robinson JP, Burwinkle T. Prevalence of fear of pain and activity in patients with fibromyalgia syndrome. J Pain. 2004;5: 483-90. [Crossref]  [PubMed] 
  10. Faul F, Erdfelder E, Buchner A, et al. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41:1149-60. [Crossref]  [PubMed] 
  11. Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatol Int. 2000;20:9-12. [Crossref]  [PubMed] 
  12. Yilmaz ÖT, Yakut Y, Uygur F ve ark. [Turkish version of the Tampa Scale for Kinesiophobia and its test-retest reliability]. Fizyoterapi Rehabilitasyon. 2011;22:44-9. [Link] 
  13. Burwinkle T, Robinson JP, Turk DC. Fear of movement: factor structure of the Tampa Scale of Kinesiophobia in patients with fibromyalgia syndrome. J Pain. 2005;6:384-91. [Crossref]  [PubMed] 
  14. Oskay D, Tuna Z, Düzgün İ, et al. Relationship between kinesiophobia and pain, quality of life, functional status, disease activity, mobility, and depres sion in patients with ankylosing spondylitis. Turk J Med Sci. 2017;47:1340-7. [Crossref]  [PubMed] 
  15. Diener E, Emmons RA, Larsen RJ, et al. The satisfaction with life scale. J Pers Assess. 1985;49:71-5. [Crossref]  [PubMed] 
  16. Vlaeyen JWS, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain: a state of the art. Pain. 2000;85:317-32. [Crossref]  [PubMed] 
  17. Leeuw M, Goossens ME, Linton SJ, et al. The fear-avoidance model of musculoskeletal pain: current state of scientific evidence. J Behav Med. 2007;30:77-94. [Crossref]  [PubMed] 
  18. Van Den Houte M, Luyckx K, Van Oudenhove L, et al. Differentiating progress in a clinical group of fibromyalgia patients during and following a multicomponent treatment program. J Psychosom Res. 2017;98:47-54. [Crossref]  [PubMed] 
  19. van Koulil S, Kraaimaat FW, van Lankveld W, et al. Screening for pain-persistence and pain-avoidance patterns in fibromyalgia. Int J Behav Med. 2008;15:211-20. [Crossref]  [PubMed] 
  20. Russek L, Gardner S, Maguire K, et al. A cross-sectional survey assessing sources of movement-related fear among people with fibromyalgia syndrome. Clin Rheumatol. 2015; 34:1109-19. [Crossref]  [PubMed]